Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice

Zhang,Xiao‑Qian; Zhang,Hong‑Mei; Sun,Xiu‑E; Yuan,Zhou‑Jie; Feng,Yu‑Guang

doi:10.3892/etm.2014.2077

Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice

Authors:
- Xiao‑Qian Zhang
- Hong‑Mei Zhang
- Xiu‑E Sun
- Zhou‑Jie Yuan
- Yu‑Guang Feng
View Affiliations

Affiliations: Department of Gastroenterology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China
Published online on: November 18, 2014 https://doi.org/10.3892/etm.2014.2077
Pages: 105-111

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

5-Fluorouracil (5‑Fu) is one of the most commonly used drugs to treat gastric cancer; however, drug‑resistance in cancer cells reduces the efficacy of 5‑Fu. Celecoxib may be able to reduce resistance to 5‑Fu chemotherapy. The aim of the present study was to investigate the inhibitory effects of a combination of 5‑Fu and celecoxib on implanted gastric cancer xenografts in nude mice and to elucidate the underlying mechanism. A tumor‑bearing nude mice model was established. The mice were divided into blank control, 5‑Fu, celecoxib and combination groups. The weight change and the tumor inhibition rate in each group were calculated. Immunocytochemistry, reverse transcription‑polymerase chain reaction and western blotting methods were used to observe hypoxia‑inducible factor‑2α (HIF‑2α), ATP‑binding cassette transporter G2 (ABCG2) and octamer-binding transcription factor 4 (Oct‑4) expression in the SGC7901 cells. Inhibition of the growth of the implanted gastric cancer was observed in the 5‑Fu, celecoxib and combination groups. In the celecoxib and combination treatment groups, the mean tumor mass was significantly less than that in the control group (P<0.05), and the mean tumor mass in the combination treatment group was significantly less than that in the 5‑Fu group (P<0.05). The tumor inhibition rates in the 5-Fu, celecoxib and combination groups were 26.36, 59.70 and 88.37%, respectively. The combination group exhibited the highest inhibition rate; the inhibition rates of the combination and celecoxib groups were significantly higher compared with the 5-Fu group (P<0.05). The expression levels of HIF‑2, ABCG2 and Oct‑4 mRNA and protein were high in the blank control group, and were further increased in the 5‑Fu group. However, in the celecoxib and combination groups, the expression levels were lower compared with those in the control group. Significant differences were identified among the 5‑Fu, celecoxib and combination groups (P<0.01). Celecoxib has antitumor effects in vivo. The mechanism may be associated with the reduced expression of cancer stem cell markers HIF‑2α, Oct‑4 and ABCG2. 5‑Fu and celecoxib have a synergistic antitumor effect. The mechanism associated with the amelioration of resistance to chemotherapy in gastric cancer and the enhancement of the effect of chemotherapy may be via the reduction of the expression of HIF‑2α, ABCG2, Oct‑4 and other cancer stem cell markers in the tumor tissues.

View Figures

View References

1	Cunningham D, Allum WH, et al: Magic Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
2	Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
3	Mathew ST, Devi SG, Prasanth VV and Vinod B: Efficacy and safety of COX-2 inhibitors in the clinical management of arthritis: Mini review. ISRN Pharmacol. 2011:4802912011. View Article : Google Scholar : PubMed/NCBI
4	Dannenberg AJ and Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 4:431–436. 2003. View Article : Google Scholar
5	Schönthal AH: Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer. 97:1465–1468. 2007. View Article : Google Scholar : PubMed/NCBI
6	Chuang HC, Kardosh A, Gaffney KJ, Petasis NA and Schönthal AH: COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer. 7:382008. View Article : Google Scholar : PubMed/NCBI
7	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
8	Agboola O: Adjuvant treatment in gastric cancer. Cancer Treat Rev. 20:217–240. 1994. View Article : Google Scholar : PubMed/NCBI
9	Cunningham D, Allum WH, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
10	Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
11	Yoshida K, Yamaguchi K, et al: Challenge for a better combination with basic evidence. Int J Clin Oncol. 13:212–219. 2008. View Article : Google Scholar : PubMed/NCBI
12	Jin Mao-Lin: New progress in advanced gastric cancer systemic chemotherapy. Waike Lilun Yushijian. 8:18–20. 2003.(In Chinese).
13	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
14	Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
15	Bertout JA, Patel SA and Simon MC: The impact of O₂ availability on human cancer. Nat Rev Cancer. 8:967–975. 2008. View Article : Google Scholar : PubMed/NCBI
16	Hu L, McArthur C and Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
17	Martin CM, Ferdous A, Gallardo T, et al: Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells. Circ Res. 102:998–1001. 2008. View Article : Google Scholar
18	Nichols J, Zevnik B, Anastassiadis K, et al: Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 95:379–391. 1998. View Article : Google Scholar : PubMed/NCBI
19	Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK and Trosko JE: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis. 26:495–502. 2005. View Article : Google Scholar
20	Covello KL, Kehler J, Yu H, et al: HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20:557–570. 2006. View Article : Google Scholar : PubMed/NCBI
21	Dallas NA, Xia L, Fan F, et al: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009. View Article : Google Scholar : PubMed/NCBI
22	Zhang XQ, Feng YG and Wu MY: Effect of 5-Fu on the ratio of SP cells and expression of HIF-2α and ABCG2 in human gastric cancer cell line SGC7901 under hypoxia. World Chinese Journal of Digestology. 20:1813–1818. 2012.(In Chinese).
23	Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 342:1946–1952. 2000. View Article : Google Scholar : PubMed/NCBI
24	Kuo CH, Hu HM, Tsai PY, Wu IC, Yang SF, Chang LL, Wang JY, Jan CM, Wang WM and Wu DC: Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. World J Gastroenterol. 15:4907–4914. 2009. View Article : Google Scholar : PubMed/NCBI
25	Rocha FT, Lourenço LG, Jucá MJ, Costa V and Leal AT: Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy. Acta Cir Bras. 24:189–194. 2009. View Article : Google Scholar : PubMed/NCBI
26	Dandekar DS, Lopez M, Carey RI and Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and-9 in prostate cancer cells. Int J Cancer. 115:484–492. 2005. View Article : Google Scholar : PubMed/NCBI
27	Ding H, Han C, Zhu J, Chen CS and D’Ambrosio SM: Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer. 113:803–810. 2005. View Article : Google Scholar
28	Li Q, Peng J and Zhan GY: Effect of a selective COX-2 inhibitor on cell proliferation and apoptosis in human gastric cancer cell line BGC-823. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 33:1123–1128. 2008.(In Chinese).
29	Kim N, Kim CH, Ahn DW, et al: Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol. 24:480–487. 2009. View Article : Google Scholar
30	Wang Z, Chen H and Xia GH: Study on celecoxib inducing gastric cancer cell apoptosis and its mechanism. Journal of Modern Oncology. 17:416–420. 2009.(In Chinese).
31	Swamy MV, Herzog CR and Rao CV: Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res. 63:5239–5242. 2003.PubMed/NCBI
32	Erkinheimo TL, Lassus H, et al: Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res. 10:538–545. 2004. View Article : Google Scholar : PubMed/NCBI
33	Krysan K, Merchant FH, et al: COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J. 18:206–208. 2004.